The Big Ones
It is the sort of line to awaken the curiosity in an annual report: “Cash payments to acquire equity investments amounted to £258m [$314m] (2018 – £309m), primarily relating to Lyell Immunopharma.”
Thus, the accountants revealed UK-listed drugs maker GlaxoSmithKline (GSK) had invested a sizeable amount in US-based cancer treatment developer Lyell Immunopharma, which raised $493m earlier this month.
Late last week, US-listed software provider Microsoft fell into the latter camp as it agreed with AnyVision that “it is in the best interest of both enterprises for Microsoft to divest its shareholding in AnyVision”.
AnyVision Interactive Technologies, an Israel-based computer vision technology provider specialising in face, body and object-recognition software, only announced the close of a $74m series A round featuring M12, Microsoft’s corporate venture fund, as a new investor, in mid-June. But the deal came under public attention with media reports alleging its system was being used for a mass surveillance program in the West Bank.
American firms have a long history of running into competition concerns when trying to buy UK-based chipmaker Plessey. The latest is social media company Facebook, which has turned from acquisition plans to an agreement just to buy all the augmented reality displays made by Plessey over the next several years.
WeWork has had its six months of hell compounded after SoftBank pulled away from a $3bn share tender offer connected to a proposed $1.5bn in debt financing. The corporate cited WeWork’s failure to meet certain conditions set in the tender agreement and said it has now supplied more than $14bn – $14bn! – in debt and equity financing for the company since it first invested just three years ago. With Covid-19 keeping office workers at home, the future looks anything but bright for the startup space’s most visible falling star.
Adapting rather better to the situation is artificial intelligence technology provider 4Paradigm, which has closed $230m in funding from investors including Lenovo and existing backer Cisco at a $2bn valuation. China-based 4Paradigm said it has been developing AI tools to track infection rates and model coronavirus-related scenarios in addition to helping businesses accelerate digital transformation. It had last raised funding in a late 2018 series D round valuing it at $1.2bn.
And despite general concerns around slowing transportation needs, Via Transportation offers a diverse range of transport options that can be integrated into an organisation’s existing activities. Holding company Exor has pumped $200m into Via as part of a series E round of undisclosed size that valued it at $2.25bn. Shell, Mori Building and Hearst Ventures also contributed to the round. Via’s existing backers include Daimler, which led a reported $250m round for the company three years ago.
And Crisitunity! The Covid-19 pandemic and the related restrictions associated with it are likely to be around for a while, but while it is devastating large swathes of the worldwide economy, some others are benefitting. Zoom and Netflix have been held up as examples of this, but the online education and media sector is also in place to do well.
Yuanfudao has reportedly topped Chinese app downloads in the space since January and has raised $1bn in a series G round co-led by long-term corporate investor Tencent. The cash was secured at a $7.8bn valuation and boosted the company’s overall funding to more than $1.5bn. Expect more to follow in that sector. Businesses are suffering but it looks as if a by-product of the crisis will be to accelerate the move toward mobile activities and socialising touted by the tech space for so long.
Tiger Global waltzes into Bytedance
As are ecommerce and producers. Plenty prepares to raise $100m
Online marketplace Ozon has been a fixture in Russia for more than two decades and is still getting big interest from investors. It’s just added $50m in convertible note financing from Princeville Capital to $100m recently secured from conglomerate Sistema and Baring Vostok. The $150m financing round follows $154m from the latter two last April and a $119m secondary investment by Sistema shortly before.
On healthcare and life sciences, which is another part of the tech space that’s unsurprisingly booming right now. Hillhouse Capital and Chen Yi Investment are putting up $292m for a secondary investment in Hualan Biological Vaccines, the vaccine developer spun off from biopharmaceutical firm Hualan Biological Engineering. It was formed in 2015 and was responsible for a third of its parent company’s revenue last year. It’s now valued at about $1.94bn.
6 Dimensions supports $125m round for iTeos
Collibra collects $112m
Pandion packs in $80m
Aspen Neuroscience ascends with $70m
Affinia affirms $60m series A
AM-Pharma has added $52m in debt and equity financing from Cowen Healthcare Investments and European Investment Bank to a round that now stands at $182m. The company, which is developing a treatment for acute kidney injury, has now disclosed almost $340m in funding altogether, its earlier backers including Pfizer and AbbVie.
Olive collects $51m
Zucara sweetens $21m series A deal
MiDiagnostics brings experiment to a $15.4m close
Yamato delivers Kuroneko Innovation Fund
OneWeb is the latest of SoftBank Vision Fund’s large-scale investments to go sour, filing for bankruptcy after failing to raise a reported $2bn from investors including Vision Fund. SoftBank has pumped upwards of $1bn into the satellite internet system developer, which has secured a total of $3.4bn prior to the move, from investors also including Qualcomm, Airbus, Coca-Cola Company, Virgin, Bharti Enterprises, Totalplay, Hughes Network Systems and Intelsat.
And distressed exits will increase. Hooq clasps liquidation option
IPOs may have dropped off but we’ve already seen some large M&A deals in recent weeks, the latest being Affirmed Networks, which has agreed to an acquisition by Microsoft that reportedly valued it at $1.35bn. The mobile network technology provider had disclosed $141m in funding and its exiting investors include Qualcomm Ventures, Vodafone and Deutsche Telekom Capital Partners, the latter having taken over the stake from another Deutsche Telekom subsidiary, T-Venture.
Palo Alto Networks agreeing to buy network technology provider CloudGenix in a $420m deal that will enable Intel Capital to exit. Longtime readers will of course recognise Palo Alto as one of the most frequent providers of CVC M&A exits.